Label Changes for:
Invanz (ertapenem) injection
December 2009
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2009
ADVERSE REACTIONS
Postmarketing Experience
- includes altered mental status (including aggression, delirium), dyskinesia, myoclonus, and tremor

